In Vivo Pharmacodynamic Characterization of T-705 in an Experimental Influenza Infection Model in Mice

被引：0
|
作者：
Takahashi, K. [1 ]
Kadota, T. [1 ]
Tanaka, T. [1 ]
Komeno, T. [1 ]
Hayakawa, H. [1 ]
Mitsuyama, J. [1 ]
Furuta, Y. [2 ]
Shiraki, K. [3 ]
机构：
[1] Toyama Chem Co LTD, Res Labs, Toyama, Japan
[2] Toyama Chem Co LTD, Business Dev Dept, Tokyo, Japan
[3] Toyama Univ, Dept Virol, Toyama 930, Japan
来源：
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES | 2008年 / 12卷
关键词：
D O I：
10.1016/j.ijid.2008.05.425
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：E170 / E171
页数：2
相关论文
共 50 条
  • [1] Characterization of Susceptibility Variants of Influenza Virus Grown in the Presence of T-705
    Daikoku, Tohru
    Yoshida, Yoshihiro
    Okuda, Tomoko
    Shiraki, Kimiyasu
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2014, 126 (03) : 281 - 284
  • [2] T-705 (Favipiravir) suppresses tumor necrosis factor a production in response to influenza virus infection: A beneficial feature of T-705 as an anti-influenza drug
    Tanaka, T.
    Kamiyama, T.
    Daikoku, T.
    Takahashi, K.
    Nomura, N.
    Kurokawa, M.
    Shiraki, K.
    ACTA VIROLOGICA, 2017, 61 (01) : 48 - 55
  • [3] In vitro and in vivo activities of anti-influenza virus compound T-705
    Furuta, Y
    Takahashi, K
    Fukuda, Y
    Kuno, M
    Kamiyama, T
    Kozaki, K
    Nomura, N
    Egawa, H
    Minami, S
    Watanabe, Y
    Narita, H
    Shiraki, K
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) : 977 - 981
  • [4] Effects of the Combination of Favipiravir (T-705) and Oseltamivir on Influenza A Virus Infections in Mice
    Smee, Donald F.
    Hurst, Brett L.
    Wong, Min-Hui
    Bailey, Kevin W.
    Tarbet, E. Bart
    Morrey, John D.
    Furuta, Yousuke
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (01) : 126 - 133
  • [5] Mechanism of action of T-705 against influenza virus
    Furuta, Y
    Takahashi, K
    Kuno-Maekawa, M
    Sangawa, H
    Uehara, S
    Kozaki, K
    Nomura, N
    Egawa, H
    Shiraki, K
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) : 981 - 986
  • [6] Optimizing T-705 (favipiravir) treatment of severe influenza B virus infection in the immunocompromised mouse model
    Pascua, Philippe Noriel Q.
    Marathe, Bindumadhav M.
    Vogel, Peter
    Webby, Richard J.
    Govorkova, Elena A.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (05) : 1333 - 1341
  • [7] Therapy of advanced arenaviral infection in hamsters with T-705
    Gowen, Brian
    Wong, Min-Hui
    Jung, Kie-Hoon
    Bailey, Kevin
    Furuta, Yousuke
    Morrey, John
    ANTIVIRAL RESEARCH, 2008, 78 (02) : A57 - A57
  • [8] Combination of Neuraminidase Inhibitors with T-705 for Treating Influenza Virus Infections in Cell Culture and in Mice
    Smee, Donald
    Wong, Min-Hui
    Bailey, Kevin
    Morrey, John
    Maekawa, Masako
    Takahashi, Kazumi
    Furuta, Yousuke
    ANTIVIRAL RESEARCH, 2009, 82 (02) : A37 - A37
  • [9] Favipiravir (T-705) protects against Nipah virus infection in the hamster model
    Dawes, Brian E.
    Kalveram, Birte
    Ikegami, Tetsuro
    Juelich, Terry
    Smith, Jennifer K.
    Zhang, Lihong
    Park, Arnold
    Lee, Benhur
    Komeno, Takashi
    Furuta, Yousuke
    Freiberg, Alexander N.
    SCIENTIFIC REPORTS, 2018, 8
  • [10] Favipiravir (T-705) protects against Nipah virus infection in the hamster model
    Brian E. Dawes
    Birte Kalveram
    Tetsuro Ikegami
    Terry Juelich
    Jennifer K. Smith
    Lihong Zhang
    Arnold Park
    Benhur Lee
    Takashi Komeno
    Yousuke Furuta
    Alexander N. Freiberg
    Scientific Reports, 8
12345